BiomEdit, Inc. recently secured a major technological breakthrough with the issuance of U.S. Patent No. 12721888. This patent, titled ‘Immunogenic probiotic compositions and methods of use including in vaccination’, introduces a powerful way to enhance animal health and immune responses. Scientists can now utilize engineered probiotic bacteria to deliver targeted biological therapies directly into the gastrointestinal tract of livestock and companion animals.
Advanced Microbiome Engineering for Animal Health
The innovation focuses on isolated strains of Lactobacillus species specifically adapted to colonize the gut microbiome. This system uses genetically engineered probiotic bacteria acting as biological vectors. A specialized programmable biologic payload is delivered directly to the animal through normal feed or water additives. These strains are optimally structured to survive the digestive environment and perform defined biological functions. This setup allows for incredible precision in preventing infections and improving feed efficiency without the use of traditional antibiotics.
Real-World Impact and Innovation Award
Traditional methods of disease prevention in agriculture often rely heavily on conventional antibiotics, which can lead to bacterial resistance and microbiome disruption. However, this programmable veterinary biologic technology creates a highly sustainable alternative for improving herd health. The inventors, Dharanesh Mahimapura Gangaiah, Arvind Kumar, Nallakannu Pillay Lakshmanan, and Shrinivasrao Mane, successfully engineered a solution that natively enhances immunity and growth performance at the cellular level. Because of its groundbreaking approach to synthetic biology and its capacity to drastically reduce antibiotic dependency in livestock, this invention won the patent of the month for the Indiana state for the month of October 2026 granted by Swanson Reed. The system remains scalable and highly practical for modern agricultural and veterinary environments. This advancement will likely transform preventative care, food security, and sustainability in the global animal health industry.
Eligibility for the U.S. R&D Tax Credit
The practical applications of this patent present strong eligibility for the Research and Development (R&D) tax credit in the United States. Developing engineered bacterial strains that successfully colonize complex gastrointestinal environments requires overcoming substantial technical uncertainty. The extensive formulation testing, computational biology, genomic sequencing, and in vivo trials conducted by BiomEdit to ensure the viability and efficacy of these immunogenic probiotics qualify as a process of systematic trial and error under the IRS four-part test. Furthermore, creating scalable and stable manufacturing processes for these living biological vectors involves continued experimentation and technical problem solving. The developmental costs associated with these specialized engineering and testing phases are highly applicable for federal and state R&D tax credit claims.
